What would the company bring, if it were put into play? If represented by a major or even Tier 2 Wall Street House, probably $5.00 plus or minus which is nothing to sneeze at, but I doubt enough shares would be secured at that price. Of course, if the offer price started to push $10, the result could be different. Its always nice to have a BO as a Plan B and the BOD understand this. At this point, Plan A is for CYDY to bring Leronlimab to market with the help of "partners", which is all well and good but,if Plan A stalls and the company is bought out, I don't think there will be too many complaints.